| Manahawkin Conv Ctr | |
| 1211 Rt 72 West, Manahawkin, New Jersey 08050 | |
| (609) 597-8500 | |
| Name | Manahawkin Conv Ctr |
|---|---|
| Location | 1211 Rt 72 West, Manahawkin, New Jersey |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 77.33% |
| Medicare ID (CCN) | 315206 |
| Legal Business Name | Mr Of Manahawkin Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1437428067 |
| Organization Name | MANAHAWKIN HEALTHCARE LP |
| Doing Business As | MANAHAWKIN NURSING AND REHABILITATION CENTER |
| Address | 1121 Rte 72 West, Manahawkin, NJ 08050 |
| Phone Number | 609-597-8500 |
News Archive
Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
The Globe and Mail examines the sustainability of Sierra Leone's free health care system, writing, "The reform has been hugely successful and the death rate has dropped sharply. ... But the country's hospitals are overwhelmed with new patients, the drug supply can't keep up, the medical staff are overloaded, and it's unclear if the $36-million program would survive without foreign donations."
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
The Globe and Mail examines the sustainability of Sierra Leone's free health care system, writing, "The reform has been hugely successful and the death rate has dropped sharply. ... But the country's hospitals are overwhelmed with new patients, the drug supply can't keep up, the medical staff are overloaded, and it's unclear if the $36-million program would survive without foreign donations."
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $8917 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.69 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.28 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 18.62 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.9 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 22.45 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.9 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.46 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.4 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.41 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.78 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 9.01 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 28.13 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 54.07 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.45 | 82.93 |
News Archive
Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
The Globe and Mail examines the sustainability of Sierra Leone's free health care system, writing, "The reform has been hugely successful and the death rate has dropped sharply. ... But the country's hospitals are overwhelmed with new patients, the drug supply can't keep up, the medical staff are overloaded, and it's unclear if the $36-million program would survive without foreign donations."
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
› Verified 9 days ago
Southern Ocean Center Location: 1361 Route 72 West, Manahawkin, New Jersey 08050 Phone: (609) 978-0600 | |
Southern Ocean Medical Center Location: 1140 Route 72 West, Manahawkin, New Jersey 08050 Phone: (609) 978-4182 |